Vibratome Sectioning of Tumors to Evaluate the Interactions Between Nanoparticles and the Tumor Microenvironment Ex-vivo

Overview

Journal Front Bioeng Biotechnol

Date 2022 Oct 10

PMID 36213072

Authors

Shuhan Liu

Juechao Zhang

Ning-Ning Zhang

Xiandi Meng

Kun Liu

Yong-Guang Yang

Tianmeng Sun

Liguang Sun

Affiliations

Soon will be listed here.

Abstract

Nanoparticles have been investigated as drug carriers and promising agents for cancer therapy. However, the tumor microenvironment (TME), which is formed by the tumor, is considered a barrier for nanocarriers to enter the internal tumor tissue. Therefore, the evaluation of the biological distribution of nanocarriers in TME can provide useful information on their role in tumor-targeted drug delivery. Although the tumor-bearing mouse model is commonly used to investigate the distribution of nanocarriers in the TME, there is currently a lack of a testing system to predict the distribution of nanocarriers in tumor tissues, especially in patients. This study revealed that the macrophages and dendritic cells (DCs) were more distributed in the peripheral part than the central part of the tumor, which might be an obstacle to the uniform distribution of nanoparticles in the tumor. In addition, the cellular uptake of gold nanoparticles (AuNR and AuNS) in macrophages and DCs cell lines (RAW264.7 and DC1.2) was markedly different from that in the TME. Hence, the study model of the interaction between nanoparticles and macrophages and DCs has an important impact on the accuracy of the results. The vibratome sections of tumor tissues preserved the spatial distribution of immune cells and tumor cells, and had very little effects on their morphologies and activities. More importantly, we found that the distribution of nanocarriers in vibratome sections was similar to that in tumors . In all, analysis using vibratome sections of tumor tissues provides a more convenient and stable method for elucidating the influences of TME on the distribution of nanocarriers.

References

Black K, Wang Y, Luehmann H, Cai X, Xing W, Pang B . Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. ACS Nano. 2014; 8(5):4385-94. PMC: 4358630. DOI: 10.1021/nn406258m. View

Xiong Y, Wang Y, Tiruthani K . Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. Nanomedicine. 2019; 21:102034. DOI: 10.1016/j.nano.2019.102034. View

Kersting D, Fasbender S, Pilch R, Kurth J, Franken A, Ludescher M . From in vitro to ex vivo: subcellular localization and uptake of graphene quantum dots into solid tumors. Nanotechnology. 2019; 30(39):395101. DOI: 10.1088/1361-6528/ab2cb4. View

Clerin E, Yang Y, Forster V, Fontaine V, Sahel J, Leveillard T . Vibratome sectioning mouse retina to prepare photoreceptor cultures. J Vis Exp. 2014; (94). PMC: 4354458. DOI: 10.3791/51954. View

Stylianopoulos T, Munn L, Jain R . Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer. 2018; 4(4):292-319. PMC: 5930008. DOI: 10.1016/j.trecan.2018.02.005. View

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y . Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5):761-773. PMC: 5381164. DOI: 10.7150/jca.17648. View

Musetti S, Huang L . Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. ACS Nano. 2018; 12(12):11740-11755. DOI: 10.1021/acsnano.8b05893. View

Overchuk M, Zheng G . Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2017; 156:217-237. DOI: 10.1016/j.biomaterials.2017.10.024. View

Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A . Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther. 2017; 184:13-41. DOI: 10.1016/j.pharmthera.2017.10.017. View

10.

Miao L, Liu Q, Lin C, Luo C, Wang Y, Liu L . Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Res. 2016; 77(3):719-731. PMC: 5290135. DOI: 10.1158/0008-5472.CAN-16-0866. View

11.

Gerlach M, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F . Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2013; 110(2):479-88. PMC: 3899754. DOI: 10.1038/bjc.2013.700. View

12.

Wu C, Chen H, Wu X, Cong X, Wang L, Wang Y . The influence of tumor-induced immune dysfunction on the immune cell distribution of gold nanoparticles in vivo. Biomater Sci. 2017; 5(8):1531-1536. DOI: 10.1039/c7bm00335h. View

13.

Joyce J, Fearon D . T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015; 348(6230):74-80. DOI: 10.1126/science.aaa6204. View

14.

Stylianopoulos T, Munn L, Jain R . Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends Cancer. 2018; 4(4):258-259. PMC: 6161778. DOI: 10.1016/j.trecan.2018.02.010. View

15.

Hou L, Liu Q, Shen L, Liu Y, Zhang X, Chen F . Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics. 2018; 8(14):3781-3796. PMC: 6071534. DOI: 10.7150/thno.24821. View

16.

Martin S, Wagner D, Horner N, Horst D, Lang H, Tagscherer K . Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer. 2019; 19(1):1030. PMC: 6824140. DOI: 10.1186/s12885-019-6270-4. View

17.

Hofmann F, Blasche R, Kasper M, Barth K . A co-culture system with an organotypic lung slice and an immortal alveolar macrophage cell line to quantify silica-induced inflammation. PLoS One. 2015; 10(1):e0117056. PMC: 4312074. DOI: 10.1371/journal.pone.0117056. View

18.

Parajuli N, Doppler W . Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs. In Vitro Cell Dev Biol Anim. 2009; 45(8):442-50. DOI: 10.1007/s11626-009-9212-7. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Sun T, Zhang Y, Pang B, Hyun D, Yang M, Xia Y . Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014; 53(46):12320-64. DOI: 10.1002/anie.201403036. View